Drugmakers, trade groups push back against Medicare drug price negotiations
Here are summaries of the cases and where they stand.
Here are summaries of the cases and where they stand.
Here are summaries of the cases and where they stand.
Here are summaries of the cases and where they stand.
Here are summaries of the cases and where they stand.
Here are summaries of the cases and where they stand.
Here are summaries of the cases and where they stand.
While antiviral pills are plentiful and remain an option for some with weak immune systems, they won’t work for everyone — Pfizer’s Paxlovid interacts with many widely prescribed drugs.
While antiviral pills are plentiful and remain an option for some with weak immune systems, they won’t work for everyone — Pfizer’s Paxlovid interacts with many widely prescribed drugs.
While antiviral pills are plentiful and remain an option for some with weak immune systems, they won’t work for everyone — Pfizer’s Paxlovid interacts with many widely prescribed drugs.
The panels began investigating Aduhelm’s approval and pricing in June 2021, just weeks after it won the FDA’s backing despite questions about the drug’s clinical benefit to patients.
The panels began investigating Aduhelm’s approval and pricing in June 2021, just weeks after it won the FDA’s backing despite questions about the drug’s clinical benefit to patients.
While antiviral pills are plentiful and remain an option for some with weak immune systems, they won’t work for everyone — Pfizer’s Paxlovid interacts with many widely prescribed drugs.
The panels began investigating Aduhelm’s approval and pricing in June 2021, just weeks after it won the FDA’s backing despite questions about the drug’s clinical benefit to patients.
The panels began investigating Aduhelm’s approval and pricing in June 2021, just weeks after it won the FDA’s backing despite questions about the drug’s clinical benefit to patients.
The panels began investigating Aduhelm’s approval and pricing in June 2021, just weeks after it won the FDA’s backing despite questions about the drug’s clinical benefit to patients.
Covid vaccines’ inclusion on the schedules don’t constitute mandates.
Covid vaccines’ inclusion on the schedules don’t constitute mandates.
Covid vaccines’ inclusion on the schedules don’t constitute mandates.
Covid vaccines’ inclusion on the schedules don’t constitute mandates.
Covid vaccines’ inclusion on the schedules don’t constitute mandates.
Covid vaccines’ inclusion on the schedules don’t constitute mandates.
Covid vaccines’ inclusion on the schedules don’t constitute mandates.
Covid vaccines’ inclusion on the schedules don’t constitute mandates.
Covid vaccines’ inclusion on the schedules don’t constitute mandates.
Covid vaccines’ inclusion on the schedules don’t constitute mandates.
The years-long effort to yank the drug’s approval offers a case study of the agency’s accelerated approval program, which green-lit Makena in 2011.
The years-long effort to yank the drug’s approval offers a case study of the agency’s accelerated approval program, which green-lit Makena in 2011.
The years-long effort to yank the drug’s approval offers a case study of the agency’s accelerated approval program, which green-lit Makena in 2011.
The years-long effort to yank the drug’s approval offers a case study of the agency’s accelerated approval program, which green-lit Makena in 2011.
The administration is making a policy change it has signaled for months.